Cannabidiol as an adjuvant treatment in adults with drug-resistant focal epilepsy
Epilepsy & Behavior · 2023-07 · 144 · 109210
DOI: 10.1016/j.yebeh.2023.109210 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Epilepsy & Behavior, 2023-07. Verfasst von Silvia Kochen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Neurosciences and Complex Systems Unit (ENyS), Epilepsy Unit, Hospital El Cruce "Nestor Kirchner". CONICET. National University Arturo Jauretche (UNA…. Hauptthemen laut MEDLINE: Cannabidiol, Drug Resistant Epilepsy, Epilepsies, Myoclonic, Epilepsies, Partial. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
Cannabidiol oil (CBD) has been approved as an anti-seizure medication for the treatment of uncommon types of epilepsy, occurring in children: Dravet syndrome, Lennox-Gastaut syndrome, and Tuberous Sclerosis Complex. There are few publications in relation to use the CBD in adult patients with focal drug-resistant epilepsy. The objective of this study was to evaluate the efficacy, tolerability, safety, and quality of life, of adjuvant treatment with CBD, in adult patients with drug-resistant focal epilepsy for at least 6 months. An open, observational, prospective cohort study was conducted using a before-after design (time series) in adult patients undergoing outpatient follow-up in a public hospital in Buenos Aires, Argentina. From a total of 44 patients, 5% of patients were seizure-free, 32% of patients reduced more than 80% of their seizures and 87% of patients reduced 50% of their monthly seizures. Eleven percent presented a decrease of less than 50% in seizure frequency. The average final dose was 335 mg/d orally administered. Thirty-four percent of patients reported mild adverse events and no patient reported severe adverse effects. At the end of the study, we found in most patients a significant improvement in the quality of life, in all the items evaluated. Adjuvant treatment with CBD in adult patients with drug-resistant focal epilepsy was effective, safe, well tolerated, and associated with a significant improvement in their quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurosciences and Complex Systems Unit (ENyS), Epilepsy Unit, Hospital El Cruce "Nestor Kirchner". CONICET. National University Arturo Jauretche (UNAJ), F. Varela, Prov. Buenos Aires, Argentina.
- Neurosciences and Complex Systems Unit (ENyS), Epilepsy Unit, Hospital El Cruce "Nestor Kirchner". CONICET. National University Arturo Jauretche (UNAJ), F. Varela, Prov. Buenos Aires, Argentina. Electronic address: silv…
Zitieren
APA
Kochen, S., Villanueva, M., Bayarres, L., Daza-Restrepo, A., Gonzalez Martinez, S., & Oddo, S. (2023). Cannabidiol as an adjuvant treatment in adults with drug-resistant focal epilepsy. Epilepsy & Behavior, 144, 109210. https://doi.org/10.1016/j.yebeh.2023.109210
Vancouver
Kochen S, Villanueva M, Bayarres L, Daza-Restrepo A, Gonzalez Martinez S, Oddo S. Cannabidiol as an adjuvant treatment in adults with drug-resistant focal epilepsy. Epilepsy & Behavior. 2023;144:109210. doi:10.1016/j.yebeh.2023.109210
BibTeX
@article{Kochen2023,
author = {Kochen, Silvia and Villanueva, Manuela and Bayarres, Liliana and Daza-Restrepo, Anilu and Gonzalez Martinez, Silvia and Oddo, Silvia},
title = {Cannabidiol as an adjuvant treatment in adults with drug-resistant focal epilepsy},
journal = {Epilepsy & Behavior},
year = {2023},
volume = {144},
pages = {109210},
doi = {10.1016/j.yebeh.2023.109210}
}
EUVIMED